Skip to main content

Table 5 Backward logistic regression of factors involved in nevirapine induced liver toxicity

From: Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy

 

OR (95%CI)

p

aOR (95%CI)

p

Male vs Female

0.19 (0.04–0.94)

0.042

0.27 (0.06–1.30)

0.102

Age (× 1 year more)

0.96 (0.88–1.04)

0.293

 

MSM vs HE

0.24 (0.01–4.51)

0.338

 

IVDUs vs HE

2.20 (0.58–8.41)

0.247

 

Other vs HE

1.36 (0.06–29.16)

0.844

 

Caucasian vs Non-Caucasian

0.67 (0.08–5.64)

0.714

 

BMI (× 1 more)

0.70 (0.51–0.94)

0.020

0.72 (0.52–1.00)

0.050

Previous AIDS

0.67 (0.08–5.56)

0.713

 

Previous therapy duration (× 1 year more)

1.05 (0.90–1.23)

0.518

 

CD4 200–500 cell/μL vs < 200 cell/μL

1.17 (0.05–25.7)

0.920

1.51 (0.07–32.23)

0.790

CD4 > 500 cell/μL vs < 200 cell/μL

3.97 (0.21–74.51)

0.357

8.12 (0.42–156.90)

0.166

HIV-RNA (× 1 log10 more)

0.80 (0.54–1.18)

0.260

 

AST (× 1 more)

1.02 (1.01–1.03)

0.008

1.01 (0.99–1.03)

0.144

ALT (× 1 more)

1.01 (1.00–1.02)

0.015

 

HCV coinfection

6.93 (1.38–34.87)

0.019

8.00 (1.27–50.29)

0.027

HBV coinfection

2.39 (0.28–20.36)

0.427

 

ARV Backbone: AZT/DDI/D4T vs ABC

0.73 (0.12–4.47)

0.731

 

ARV Backbone: TDF vs ABC

0.12 (0.01–3.141)

0.204

 

ARV Backbone: Other vs ABC

0.49 (0.02–13.47)

0.672

 

ABCB1 rs1045642 CT/TT vs CC

0.18 (0.04–0.76)

0.020

0.10 (0.02–0.47)

0.004

  1. Abbreviations: OR Odds Ratio, aOR adjusted Odds Ratio, CI confidence interval, HE Heterosexual, MSM Man how have sex with man, IVDUs Intra venous drug users, BMI Body Mass Index, cps copies, ABC abacavir, TDF tenofovir diproxil fumarate, BMI Body Mass Index, ABCB ATP Binding Cassette Subfamily B